SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-17

Study Completion Date

2024-11-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants

NCT07220889

Safety After Oral Intake

RECRUITING PHASE1

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004

NCT04277910

Healthy

COMPLETED PHASE1

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

NCT02657122

Healthy

COMPLETED PHASE1

Single Ascending Dose Study of TD-0714 in Healthy Subjects

NCT02639078

Healthy

COMPLETED PHASE1

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

NCT03676322

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a first-in-human study in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics (PK), with additional exploratory objective to assess pharmacodynamics (PD) of a single dose of MDI-2517.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety and Tolerability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

2 sentinel patients will be treated with one dose of MDI-2517 or placebo and if safe after 48h, 6 additional patients will be dosed (5 on MDI-2517 and 1 on placebo). Progression to enroll the next new group of patients will happen after review of safety and available PK data by the Safety Review Committee (SRC). The SRC will decide to move to the next dose level, decrease the next dose level, repeat a dose level, or to not evaluate any additional doses. Patients are randomized to MDI-2517 or Placebo.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

This is a placebo controlled double blind study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Ascending Dose (SAD) 1

MDI-2517 tablet, single oral dose or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

SAD 2

less than or equal to twice the highest MDI2517 dose administered to date, or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

SAD 3

less than or equal to twice the highest MDI2517 dose administered to date, or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

SAD 4

less than or equal to twice the highest MDI2517 dose administered to date, or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

SAD 5

less than or equal to twice the highest MDI2517 dose administered to date, or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

SAD 6

less than or equal to twice the highest MDI2517 dose administered to date, or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

SAD 7

less than or equal to twice the highest MDI2517 dose administered to date, or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

SAD 8

less than or equal to twice the highest MDI2517 dose administered to date, or placebo

Group Type ACTIVE_COMPARATOR

MDI-2517

Intervention Type DRUG

study drug

Placebo

Intervention Type OTHER

matching placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MDI-2517

study drug

Intervention Type DRUG

Placebo

matching placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to understand the study procedures and provide signed informed consent, which includes following the requirements in the informed consent form (ICF) and protocol.
2. Healthy male and female participants from 18 to 55 years, at the time of signing the informed consent.
3. Body weight of a minimum 50 kg for men and 45 kg for women and body mass index (BMI) within the range of 18.5 to 30 kg/m2.
4. Participants who are generally healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
5. Contraceptive use by men or women consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants should be postmenopausal, surgically sterilized, or if of childbearing potential they must agree to use effective contraception throughout the study. Women of childbearing potential and those with less than 24 weeks from menopause must undergo a urine pregnancy test at screening and the result must be negative.
6. Participants must not eat Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices from 7 days before participants check into the clinical site until collection of the final sample.
7. Participants must not eat or drink caffeine- or xanthine-containing products (eg, coffee, black/green tea, cola drinks, and chocolate) or energy drinks for 48 hours before participants check into the clinical site until after collection of the final PK and/or PD sample.
8. Participants must nor drink alcohol for 24 hours before admission to the clinical site until after collection of the final PK and/or PD sample.

Exclusion Criteria

1. Major medical illness or unstable medical condition within 6 months of screening that affect the participant's ability to complete the study procedures follow restrictions, or affect the ability to interpret safety data that would prevent completion of study procedures or assessments.
2. Any clinically significant abnormal finding at physical examination. Absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
3. Chronic or ongoing active infectious disease requiring systemic treatment
4. Any acute infections within 14 days of screening.
5. Vaccination received within 1 month of screening.
6. Participants known or suspected of not being able to comply with this study (eg, due to alcoholism, drug dependency or psychological disorder).
7. Any clinically significant lab abnormalities
8. Abnormal ECG findings
9. Abnormal screening estimated glomerular filtration rate
10. Positive test results for Hepatitis B, hepatitis C virus antibody, or human immunodeficiency virus (HIV). Negative evaluation for coronavirus disease 2019 (COVID-19).
11. History of significant allergic reactions to any drug.
12. Use of prescription or nonprescription drugs, including vitamins, herbal and dietary supplements within 7 days or 5 half-lives prior to the first dose of study drug
13. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs, eg, acetylsalicylic acid) or selective serotonin reuptake inhibitors within 7 days prior to screening.
14. Positive urine cotinine test. Use of tobacco products or uses other nicotine-containing products from screening until final follow-up visit. Use of cigarettes 3 months before screening until final visit.
15. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 7 units for women or 14 units for men of alcohol per week
16. History of drug abuse within 1 year prior to screening or recreational use of soft drugs within 1 month or hard drugs within 3 months prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes